Seelos Therapeutics, Inc.

NASDAQ:SEEL

0.37 (USD) • At close November 18, 2024
Bedrijfsnaam Seelos Therapeutics, Inc.
Symbool SEEL
Munteenheid USD
Prijs 0.37
Beurswaarde 214,970
Dividendpercentage 0%
52-weken bereik 0.37 - 0.37
Industrie Biotechnology
Sector Healthcare
CEO Dr. Raj Mehra J.D., Ph.D.
Website https://seelostherapeutics.com

An error occurred while fetching data.

Over Seelos Therapeutics, Inc.

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive

Vergelijkbare Aandelen

Entera Bio Ltd. logo

Entera Bio Ltd.

ENTX

2.72 USD

Oncolytics Biotech Inc. logo

Oncolytics Biotech Inc.

ONCY

0.93 USD

Dyadic International, Inc. logo

Dyadic International, Inc.

DYAI

1.96 USD

Achieve Life Sciences, Inc. logo

Achieve Life Sciences, Inc.

ACHV

3.55 USD

Qilian International Holding Group Limited logo

Qilian International Holding Group Limited

QLI

5.41 USD

Bolt Biotherapeutics, Inc. logo

Bolt Biotherapeutics, Inc.

BOLT

0.616 USD

Lantern Pharma Inc. logo

Lantern Pharma Inc.

LTRN

4.19 USD

BioVie Inc. logo

BioVie Inc.

BIVI

2.23 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)